Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient Mice

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Caso, Giuseppe ^a   Barry, Catherine ^b   Patejunas, Gerald ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER GROWTH FACTOR; CD31 ANTIBODY; CD45 ANTIGEN; CHEMOKINE; CXCL9 CHEMOKINE; EARLY GROWTH RESPONSE FACTOR 1; UNCLASSIFIED DRUG; CXCL9 PROTEIN, MOUSE; EGR1 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA CELL; CONTROLLED STUDY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IMPLANTATION; LEWIS CARCINOMA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL9; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; KILLER CELLS, NATURAL; LEUKEMIC INFILTRATION; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; TUMOR BURDEN;

EID: 67651171675     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-7     Document Type: Article

References (29)

1. Farber JM: A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 1990, 87:5238-42.
2. Romagnani P, Annunziato F, Lazzeri E, Cosmi L, Beltrame C, Lasagni L, Galli G, Francalanci M, Manetti R, Marra F, Vanini V, Maggi E, Romagnani S: Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in human thymus. Blood 2001, 97:601-7.
3. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL: The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4:155-60.
4. Walser TC, Ma X, Kundu N, Dorsey R, Goloubeva O, Fulton AM: Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007, 30:490-498.
5. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997, 89:2635-43.
6. Hallahan DE, Sukhatme VP, Sherman ML, Virudachalam S, Kufe D, Weichselbaum RR: Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 1991, 88:2156-60.
7. Christy BA, Lau LF, Nathans D: A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. Proc Natl Acad Sci USA 1988, 85:7857-61.
8. Khachigian LM, Anderson KR, Halnon NJ, Gimbrone MA Jr, Resnick N, Collins T: Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stressresponse element in the PDGF A-chain promoter. Arterioscler Thromb Vasc Biol 1997, 17:2280-6.
9. Yang W, Li XY: Anti-tumor effect of pEgr-interferon-gammaendostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism. Chin Med J 2005, 118:296-301.
10. MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR: Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 2007, 24:521-31.
11. Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J, Wagner O, Bischoff M, Clauss M, Binder BR, Hofer E: Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res 2006, 66:6708-13.
12. Mitchell A, Dass CR, Sun LQ, Khachigian LM: Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res 2004, 32:3065-9.
13. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM: Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003, 9:1026-32.
14. Schalch P, Patejunas G, Retuerto M, Sarateanu S, Milbrandt J, Thakker G, Kim D, Carbray J, Crystal RG, Rosengart TK: Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J Thorac Cardiovasc Surg 2004, 128:595-601.
15. Sasano H, Suzuki T: Pathological evaluation of angiogenesis in human tumor. Biomed Pharmacother 1989, 59 (Suppl 2) :S334-6.
16. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11:247-61.
17. Biesiada E, Razandi M, Levin ER: Egr-1 activates basic fibroblast growth factor transcription: mechanistic implications for astrocyte proliferation. J Biol Chem 1996, 271:18576-81.
18. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M: Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1994, 1219:413-21.
19. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, Lee OH, Park BC, Kim KW: Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 1999, 59:5989-94.
20. Cenci S, Weitzmann MN, Gentile MA, Aisa MC, Pacifici R: M-CSF neutralization and egr-1 deficiency prevent ovariectomyinduced bone loss. J Clin Invest 2000, 105:1279-87.
21. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997, 61:246-57.
22. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K: Interferon-inducible T cell alpha chemoattractant (I-TAC) : a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-21.
23. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L, Tosato G: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998, 64:384-92.
24. Wald O, Weiss ID, Wald H, Shoham H, Bar-Shavit Y, Beider K, Galun E, Weiss L, Flaishon L, Shachar I, Nagler A, Lu B, Gerard C, Gao JL, Mishani E, Farber J, Peled A: IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 2006, 176:4716-29.
25. Lee SL, Wang Y, Milbrandt J: Unimpaired macrophage differentiation and activation in mice lacking the zinc finger transplantation factor NGFI-A (EGR1). Mol Cell Biol 1996, 16:4566-72.
26. Carter JH, Tourtellotte WG: Early growth response transcriptional regulators are dispensable for macrophage differentiation. J Immunol 2007, 178:3038-47.
27. Wang YQ, Wada A, Ugai S, Tagawa M: Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. Oncol Rep 2003, 10:909-13.
28. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, Ehrengruber MU, Chen YE: Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003, 315:33-41.
29. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J: Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001, 7:101-7.